Home Merck Presents Findings from Phase 1b Study of Investigational BACE Inhibitor, MK-8931, in Patients with Alzheimers Disease
 

Keywords :   


Merck Presents Findings from Phase 1b Study of Investigational BACE Inhibitor, MK-8931, in Patients with Alzheimers Disease

2013-07-14 14:30:00| Merck.com - Research & Development News

Dateline City:  WHITEHOUSE STATION, N.J. Merck, known as MSD outside the United States and Canada, today announced the presentation of results from a Phase Ib study showing a dose-dependent decrease in amyloid levels in cerebral spinal fluid (CSF) following administration of MK-8931, Mercks investigational oral -site amyloid precursor protein cleaving enzyme (BACE1 or secretase) inhibitor, in patients with mild to moderate Alzheimers disease (AD). In the study, amyloid levels were analyzed as a measure of BACE activity. Language:  English Ticker Slug:  Ticker: MRK Exchange: NYSE read more

Tags: with study phase disease

Category:Biotechnology and Pharmaceuticals

Latest from this category

All news

»
23.11PlayStationVitaPCH-2000
23.11GB
23.11 Malbon
23.11PING PEARL GATES
23.11WATCH
23.11L
23.11Tetsuya_SP2 DMC
23.116
More »